Výsledky vyhledávání - "Immunologic Factors/therapeutic use"
-
1
Autoři: a další
Zdroj: Mult Scler
Multiple sclerosis, vol. 31, no. 8, pp. 932-943Témata: escalation, personalized treatment strategies, Original Research Papers, serum neurofilament light chain, Delphi study, de-escalation, ddc, Humans, Neurofilament Proteins/blood, Delphi Technique, Multiple Sclerosis/blood, Multiple Sclerosis/drug therapy, Algorithms, Precision Medicine/methods, Clinical Decision-Making/methods, Adult, Female, Male, Consensus, Immunologic Factors/therapeutic use, Middle Aged
Popis souboru: application/pdf
Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/40296363
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_E29543626C116
https://serval.unil.ch/resource/serval:BIB_E29543626C11.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_E29543626C11
https://mediatum.ub.tum.de/doc/1791698/document.pdf -
2
Autoři: a další
Přispěvatelé: a další
Zdroj: J Neurol
Journal of neurology, vol. 272, no. 8, pp. 491Témata: Smoldering MS, Original Communication, PRLs, PIRA, Teriflunomide, Humans, Nitriles, Crotonates/therapeutic use, Crotonates/pharmacology, Hydroxybutyrates, Toluidines/therapeutic use, Toluidines/pharmacology, Female, Male, Adult, Antibodies, Monoclonal, Humanized/therapeutic use, Antibodies, Monoclonal, Humanized/pharmacology, Multiple Sclerosis, Relapsing-Remitting/drug therapy, Multiple Sclerosis, Relapsing-Remitting/diagnostic imaging, Multiple Sclerosis, Relapsing-Remitting/pathology, Middle Aged, Longitudinal Studies, Immunologic Factors/therapeutic use, Immunologic Factors/pharmacology, Brain/diagnostic imaging, Brain/pathology, Brain/drug effects, Disease Progression, Treatment Outcome, Diffusion Tensor Imaging, Magnetic Resonance Imaging, Follow-Up Studies, Disease-modifying therapies, Ocrelizumab
Popis souboru: application/pdf
-
3
Autoři: a další
Přispěvatelé: a další
Zdroj: J Neurol
Témata: LRP6, Male, Adult, Sweden, Original Communication, Multiple Sclerosis, Natalizumab, Middle Aged, Polymorphism, Single Nucleotide, ddc, Neurology and psychiatry, Multiple sclerosis, Treatment Outcome, Italy, Pharmacogenetics, Germany, GRB2, multiple sclerosis, pharmacogenomics, Humans, Immunologic Factors, Female, Pharmacogenomics, Italy [MeSH], Female [MeSH], Polymorphism, Single Nucleotide [MeSH], Adult [MeSH], Humans [MeSH], Sweden [MeSH], Multiple Sclerosis/drug therapy [MeSH], Treatment Outcome [MeSH], Middle Aged [MeSH], Genome-Wide Association Study [MeSH], Multiple Sclerosis/genetics [MeSH], Male [MeSH], Germany [MeSH], Natalizumab/therapeutic use [MeSH], Immunologic Factors/therapeutic use [MeSH], Pharmacogenetics [MeSH], Genome-Wide Association Study
Popis souboru: application/pdf
-
4
Autoři: a další
Přispěvatelé: a další
Zdroj: J Neurol
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Journal of Neurology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Institut de Recerca Germans Trias i Pujol (IGTP)
Journal of neurology, Vol. 271, no.9, p. 5813-5824 (2024)
JOURNAL OF NEUROLOGYTémata: Male, Adult, Multiple Sclerosis, Immunologic Factors / therapeutic use, cladribine, multiple sclerosis, COVID-19 / epidemiology, Multiple sclerosis, 03 medical and health sciences, natalizumab, Fingolimod Hydrochloride / therapeutic use, 0302 clinical medicine, Medicine and Health Sciences, Practice Patterns, Physicians' / statistics & numerical data, Disease-modifying therapy, Humans, Immunologic Factors, Longitudinal Studies, Practice Patterns, Physicians', Alemtuzumab, Original Communication, Fingolimod Hydrochloride, Anti-CD20 monoclonal antibodies, Natalizumab, COVID-19, Multiple Sclerosis / epidemiology, Middle Aged, anti-CD20 monoclonal antibodies, Alemtuzumab / therapeutic use, disease-modifying therapy, 3. Good health, Natalizumab / therapeutic use, Cladribine, Cladribine / therapeutic use, Multiple Sclerosis / drug therapy, Female, Immunosuppressive Agents / therapeutic use, Immunosuppressive Agents
Popis souboru: application/pdf
Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38935148
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=15109
https://ddd.uab.cat/record/311584
https://hdl.handle.net/2078.1/301596
https://hdl.handle.net/11697/238140
https://doi.org/10.1007/s00415-024-12518-7
https://urn.nsk.hr/urn:nbn:hr:105:528442
https://doi.org/10.1007/s00415-024-12518-7
https://avesis.erciyes.edu.tr/publication/details/c199e810-e5bd-4678-aade-ceb02f0551d3/oai
https://biblio.ugent.be/publication/01J718P0F63GV3RR1VJQ2E62TH/file/01J718VD4T63KKTKR1MC7SSSFZ
https://biblio.ugent.be/publication/01J718P0F63GV3RR1VJQ2E62TH
http://hdl.handle.net/1854/LU-01J718P0F63GV3RR1VJQ2E62TH
http://doi.org/10.1007/s00415-024-12518-7 -
5
Autoři:
Zdroj: Current Opinion in Critical Care. 30:420-426
Témata: hydroxychloroquine, Biomedical Research, SARS-CoV-2, Immunomodulating Agents/therapeutic use, coronavirus, COVID-19, immunomodulation, Immunologic Factors/therapeutic use, COVID-19 Drug Treatment, coronavirus disease 2019, Immunomodulating Agents, 03 medical and health sciences, antivirals, 0302 clinical medicine, Humans, Immunologic Factors, Pandemics, plasma, severe acute respiratory syndrome coronavirus 2, COVID-19/epidemiology
-
6
Autoři: a další
Zdroj: Clinical Microbiology and Infection. 30:611-618
Témata: Glucocorticoids/therapeutic use, IL-6 inhibitors, Immunomodulation, Immunomodulating Agents, Baricitinib, Humans, Janus Kinase Inhibitors, Immunologic Factors, Glucocorticoids, Randomized Controlled Trials as Topic, COVID-19/mortality, JAK inhibitors, SARS-CoV-2, Interleukin-6, Immunomodulating Agents/therapeutic use, Janus Kinase Inhibitors/therapeutic use, COVID-19, Tocilizumab, 16. Peace & justice, Immunologic Factors/therapeutic use, COVID-19 Drug Treatment, 3. Good health, Coronavirus, Interleukin-6/antagonists & inhibitors, Practice Guidelines as Topic, Complement inhibitors
-
7
Autoři: a další
Zdroj: J Neurol
Témata: Male, Adult, Original Communication, Multiple Sclerosis, Relapsing-Remitting, Time Factors, Natalizumab, Cost-Benefit Analysis, Female [MeSH], Cost-Benefit Analysis [MeSH], Adult [MeSH], Humans [MeSH], Computer Simulation [MeSH], Time Factors [MeSH], Immunologic Factors/economics [MeSH], Multiple sclerosis, Male [MeSH], Multiple Sclerosis, Relapsing-Remitting/drug therapy [MeSH], Markov Chains [MeSH], Cost–consequence, Health economics, Natalizumab/therapeutic use [MeSH], Immunologic Factors/therapeutic use [MeSH], Natalizumab/economics [MeSH], Treatment strategies, Markov model, Multiple Sclerosis, Relapsing-Remitting/economics [MeSH], Economic evaluation, Humans, Immunologic Factors, Female, Computer Simulation, Markov Chains
Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39821478
https://repository.publisso.de/resource/frl:6521505 -
8
Autoři: a další
Zdroj: J Neurol
Témata: Male, Adult, Sex Characteristics, Original Communication, Multiple Sclerosis, Clinical Decision-Making, Middle Aged, Cohort Studies, 03 medical and health sciences, Multiple Sclerosis, Relapsing-Remitting, Sex Factors, 0302 clinical medicine, Austria, Humans, Immunologic Factors, Female, Registries, Multiple Sclerosis/diagnostic imaging [MeSH], Multiple Sclerosis, Relapsing-Remitting/diagnostic imaging [MeSH], Clinical Decision-Making [MeSH], Female [MeSH], Multiple Sclerosis/therapy [MeSH], Adult [MeSH], Humans [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Gender, Cohort Studies [MeSH], Multiple Sclerosis, Relapsing-Remitting/physiopathology [MeSH], Multiple sclerosis, Male [MeSH], Sex, Immunologic Factors/therapeutic use [MeSH], Treatment, Austria/epidemiology [MeSH], Sex Characteristics [MeSH], Sex Factors [MeSH], Registry, Registries [MeSH], Retrospective Studies
Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38441611
https://repository.publisso.de/resource/frl:6500335 -
9
Autoři: a další
Zdroj: Dig Dis Sci
Digestive Diseases and Sciences
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Institut de Recerca Germans Trias i Pujol (IGTP)
DIGESTIVE DISEASES AND SCIENCES
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
r-FISABIO. Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Témata: 0301 basic medicine, STRIDE II recommendations, Crohn Disease/drug therapy [MeSH], Treat to target strategy, Colitis, Ulcerative/diagnosis [MeSH], Inflammatory Bowel Diseases/epidemiology [MeSH], Humans [MeSH], Inflammatory Bowel Diseases/drug therapy [MeSH], Crohn Disease/diagnosis [MeSH], Spain/epidemiology [MeSH], Cross-Sectional Studies [MeSH], Inflammatory bowel diseases, Original Article, Colitis, Ulcerative/drug therapy [MeSH], Quality of Life [MeSH], Immunologic Factors/therapeutic use [MeSH], Crohn's disease, Ulcerative colitis, Inflammatory Bowel Diseases, 3. Good health, 03 medical and health sciences, Cross-Sectional Studies, 0302 clinical medicine, Crohn Disease, Spain, Quality of Life, Humans, Immunologic Factors, Colitis, Ulcerative
Popis souboru: application/pdf
Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38217680
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=14777
https://fundanet.isabial.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=10126
https://link.springer.com/article/10.1007/s10620-023-08220-9
https://fisabio.portalinvestigacion.com/publicaciones/16492
https://ddd.uab.cat/record/302118
https://repository.publisso.de/resource/frl:6502444 -
10
Autoři: a další
Zdroj: BADBIR study groups & BSTOP Study Group 2024, 'The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis : a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)', The British journal of dermatology, vol. 190, no. 5, ljad481, pp. 689-700. https://doi.org/10.1093/bjd/ljad481
Témata: Adult, Biological Factors/therapeutic use, HLA-C Antigens, Etanercept, Cohort Studies, Biological Factors, Adjuvants, Immunologic, Adalimumab/therapeutic use, Etanercept/therapeutic use, Psoriasis/drug therapy, Humans, Psoriasis, Immunologic Factors, Adjuvants, Registries, Biological Products, Adalimumab, Adjuvants, Immunologic/therapeutic use, Immunologic Factors/therapeutic use, Ustekinumab/therapeutic use, 3. Good health, Treatment Outcome, Ustekinumab, Biological Products/therapeutic use, Immunologic/therapeutic use, Dermatologists
Popis souboru: application/vnd.openxmlformats-officedocument.wordprocessingml.document
Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38051972
-
11
Autoři: a další
Zdroj: Alabas, O A, Mason, K J, Yiu, Z Z N, Warren, R B, Lunt, M, Smith, C H & Griffiths, C E M 2023, 'Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis : a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)', British Journal of Dermatology, vol. 189, no. 3, pp. 271-278. https://doi.org/10.1093/bjd/ljad179
BADBIR Study Group 2023, 'Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis : A cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)', The British journal of dermatology, vol. 189, no. 3, ljad179, pp. 271-278. https://doi.org/10.1093/bjd/ljad179Témata: Biological Products/adverse effects, Adult, Male, Methotrexate/adverse effects, Biological Factors/therapeutic use, Adalimumab/adverse effects, Severity of Illness Index, Etanercept, Cohort Studies, Biological Factors, Adjuvants, Immunologic, Etanercept/therapeutic use, Psoriasis/drug therapy, Humans, Immunologic Factors, Psoriasis, Adjuvants, Biological Products, Adalimumab, Adjuvants, Immunologic/therapeutic use, Immunologic Factors/therapeutic use, 3. Good health, Methotrexate, Treatment Outcome, Female, Immunologic/therapeutic use, Dermatologists
Popis souboru: application/pdf
-
12
Autoři: a další
Zdroj: Alimentary Pharmacology & Therapeutics. 58:48-59
Témata: Adult, Mesalamine/therapeutic use, Adrenal Cortex Hormones/therapeutic use, Colitis, Inflammatory Bowel Diseases, Immunologic Factors/therapeutic use, 3. Good health, Cohort Studies, Crohn Disease, Ulcerative/drug therapy, Adrenal Cortex Hormones, Inflammatory Bowel Diseases/drug therapy, Crohn Disease/drug therapy, Humans, Immunologic Factors, Colitis, Ulcerative, Mesalamine, Aged
-
13
Autoři: a další
Přispěvatelé: a další
Zdroj: CNS Drugs
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Arteaga-Henríquez, G, Gisbert, L & Ramos-Quiroga, J A 2023, 'Immunoregulatory and/or Anti-inflammatory Agents for the Management of Core and Associated Symptoms in Individuals with Autism Spectrum Disorder : A Narrative Review of Randomized, Placebo-Controlled Trials', CNS Drugs, vol. 37, no. 3, pp. 215-229. https://doi.org/10.1007/s40263-023-00993-xTémata: Autisme - Tractament, Other subheadings::Other subheadings::/therapeutic use, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Autism Spectrum Disorder, Prednisolone, Otros calificadores::Otros calificadores::/uso terapéutico, Anti-Inflammatory Agents, Prednisolone/therapeutic use, Antiinflamatoris - Ús terapèutic, Minocycline, Review Article, Minocycline/therapeutic use, Anti-Inflammatory Agents/therapeutic use, Autism Spectrum Disorder/drug therapy, Celecoxib/therapeutic use, Fatty Acids, Omega-3, Humans, Immunologic Factors, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinflamatorios, Fatty Acids, Omega-3/therapeutic use, Randomized Controlled Trials as Topic, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Inflammatory Agents, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Immunologic Factors/therapeutic use, Acetylcysteine, 3. Good health, Celecoxib, PSIQUIATRÍA Y PSICOLOGÍA::trastornos mentales::trastornos del desarrollo neurológico::trastornos generalizados del desarrollo del niño::trastorno del espectro del autismo, Acetylcysteine/therapeutic use, PSYCHIATRY AND PSYCHOLOGY::Mental Disorders::Neurodevelopmental Disorders::Child Development Disorders, Pervasive::Autism Spectrum Disorder
Popis souboru: application/pdf
Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/36913130
https://hdl.handle.net/11351/9275
https://pure.au.dk/ws/files/379492205/s40263-023-00993-x.pdf
https://pure.au.dk/ws/files/379492205/s40263-023-00993-x.pdf
https://pure.au.dk/portal/en/publications/abfbe5f3-621a-4046-b19a-418c67c54897
http://www.scopus.com/inward/record.url?scp=85149993624&partnerID=8YFLogxK
https://doi.org/10.1007/s40263-023-00993-x -
14
Autoři: a další
Přispěvatelé: a další
Zdroj: Merola, J F, Landewé, R, McInnes, I B, Mease, P J, Ritchlin, C T, Tanaka, Y, Asahina, A, Behrens, F, Gladman, D D, Gossec, L, Gottlieb, A B, Thaçi, D, Warren, R B, Ink, B, Assudani, D, Bajracharya, R, Shende, V, Coarse, J & Coates, L C 2023, 'Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors : a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)', Lancet (London, England), vol. 401, no. 10370, pp. 38-48. https://doi.org/10.1016/S0140-6736(22)02303-0
Témata: Monoclonal/adverse effects, Adult, Tumor Necrosis Factor-alpha/antagonists & inhibitors, Tumor Necrosis Factor-alpha, Arthritis, Arthritis, Psoriatic, Interleukin-17, Antibodies, Monoclonal, Arthritis, Psoriatic/drug therapy, Antibodies, Monoclonal/adverse effects, Immunologic Factors/therapeutic use, Severity of Illness Index, Antibodies, 3. Good health, [SDV] Life Sciences [q-bio], 03 medical and health sciences, Treatment Outcome, 0302 clinical medicine, Double-Blind Method, Psoriatic/drug therapy, Humans, Immunologic Factors
Popis souboru: application/pdf
-
15
Autoři:
Zdroj: Handbook of Clinical Neurology ISBN: 9780323902427
Témata: B-Lymphocytes, Multiple Sclerosis, T-Lymphocytes, Humans, Immunologic Factors, Animals, B-Lymphocytes/immunology, Multiple Sclerosis/immunology, T-Lymphocytes/immunology, Immunologic Factors/therapeutic use, 12. Responsible consumption, 3. Good health
-
16
Autoři: a další
Zdroj: Ten Bokkel Huinink, S, Beelen, E M J, Ten Bokkel Huinink, T, Hoentjen, F, G. L. Bodelier, A, Dijkstra, G, Romberg-Camps, M, De Boer, N K, Stassen, L P S, Van Der Meulen, A E, West, R, Van Ruler, O, Van Der Woude, C J & De Vries, A C 2023, 'Retreatment with anti-tumor necrosis factor therapy in combination with an immunomodulator for recurrence of Crohn's disease after ileocecal resection results in prolonged continuation as compared to anti-tumor necrosis factor monotherapy', European Journal of Gastroenterology and Hepatology, vol. 35, no. 1, pp. 45-51. https://doi.org/10.1097/MEG.0000000000002474
European Journal of Gastroenterology & Hepatology, 35, 1, pp. 45-51Témata: Tumor Necrosis Factor-alpha, tumor necrosis factor inhibitors, Radboud University Medical Center, Crohn Disease/diagnosis, Immunologic Factors/therapeutic use, Radboudumc 5: Inflammatory diseases Gastroenterology, 3. Good health, Cohort Studies, Crohn's disease, 03 medical and health sciences, Necrosis, 0302 clinical medicine, Tumor Necrosis Factor Inhibitors/adverse effects, Crohn Disease, Retreatment, ileocecal resection, Humans, Immunologic Factors, Tumor Necrosis Factor Inhibitors, retreatment
-
17
Autoři: a další
Zdroj: Br J Dermatol
Témata: Quality of Life/psychology, Neoplasms, Second Primary, Original Articles, Survivorship, Immunologic Factors/therapeutic use, 3. Good health, 03 medical and health sciences, Second Primary, 0302 clinical medicine, SDG 3 - Good Health and Well-being, Neoplasms, Melanoma/pathology, Quality of Life, Humans, Immunologic Factors, Immunotherapy, Survivors, Survivors/psychology, Immune Checkpoint Inhibitors, Melanoma
-
18
Autoři: a další
Přispěvatelé: a další
Zdroj: Korean J Intern Med
The Korean Journal of Internal Medicine, Vol 37, Iss 5, Pp 1061-1069 (2022)Témata: Male, Male Middle Aged, rheumatoid, antirheumatic agents, Immunologic Factors / therapeutic use, Golimumab, Antibodies, Arthritis, Rheumatoid, 03 medical and health sciences, 0302 clinical medicine, Republic of Korea, Humans, Immunologic Factors, Biological therapy, golimumab, Retrospective Studies, Monoclonal* / therapeutic use, Arthritis, Antirheumatic Agents / therapeutic use, Antibodies, Monoclonal, Withholding Treatment, Middle Aged, Antirheumatic agents, 3. Good health, Treatment Outcome, arthritis, biological therapy, Antirheumatic Agents, Quality of Life, Medicine, Original Article, Female, Rheumatoid* / drug therapy, Rheumatoid* / diagnosis
-
19
Autoři: a další
Zdroj: Aliment Pharmacol Ther
Alimentary Pharmacology & Therapeutics, 56, 8, pp. 1250-1263
Chanchlani, N, Lin, S, Auth, M K, Lee, C L, Robbins, H, Looi, S, Murugesan, S V, Riley, T, Preston, C, Stephenson, S, Cardozo, W, Sonwalkar, S A, Allah-ditta, M, Mansfield, L, Durai, D, Baker, M, London, I, London, E, Gupta, S, Di Mambro, A, Murphy, A, Gaynor, E, Jones, K D J, Claridge, A, Sebastian, S, Ramachandran, S, Selinger, C P, Borg-bartolo, S P, Knight, P, Sprakes, M B, Burton, J, Kane, P, Lupton, S, Fletcher, A, Gaya, D R, Colbert, R, Seenan, J P, Macdonald, J, Lynch, L, Mclachlan, I, Shields, S, Hansen, R, Gervais, L, Jere, M, Akhtar, M, Black, K, Henderson, P, Russell, R K, Lees, C W, Derikx, L A A P, Lockett, M, Betteridge, F, De Silva, A, Hussenbux, A, Beckly, J, Bendall, O, Hart, J W, Thomas, A, Hamilton, B, Gordon, C, Chee, D, Mcdonald, T J, Nice, R, Parkinson, M, Gardner-thorpe, H, Butterworth, J R, Javed, A, Al-shakhshir, S, Yadagiri, R, Maher, S, Pollok, R C G, Ng, T, Appiahene, P, Donovan, F, Lok, J, Chandy, R, Jagdish, R, Baig, D, Mahmood, Z, Marsh, L, Moss, A, Abdulgader, A, Kitchin, A, Walker, G J, George, B, Lim, Y, Gulliver, J, Bloom, S, Theaker, H, Carlson, S, Cummings, J R F, Livingstone, R, Beale, A, Carter, J O, Bell, A, Coulter, A, Snook, J, Stone, H, Kennedy, N A, Goodhand, J R & Ahmad, T 2022, ' Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF Therapy (IMSAT) therapeutic drug monitoring study ', Alimentary Pharmacology and Therapeutics, vol. 56, no. 8, pp. 1250-1263 . https://doi.org/10.1111/apt.17170, https://doi.org/10.1111/apt.v56.8Témata: therapeutic drug monitoring, immunogenicity, Antibodies, 03 medical and health sciences, 0302 clinical medicine, Adalimumab/therapeutic use, Inflammatory Bowel Diseases/drug therapy, Tumor Necrosis Factor Inhibitors/therapeutic use, adalimumab, antibodies, Humans, Immunologic Factors, Radboudumc 5: Inflammatory diseases RIMLS: Radboud Institute for Molecular Life Sciences, drug persistence, treatment failure, Retrospective Studies, Tumor Necrosis Factor-alpha, Adalimumab, anti-TNF, Inflammatory Bowel Diseases, Immunologic Factors/therapeutic use, Infliximab, 3. Good health, Biological Therapy, Infliximab/therapeutic use, Tumor Necrosis Factor Inhibitors, Drug Monitoring, infliximab, Sequential Biologic Therapy in IBD
Popis souboru: application/pdf
Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/36039036
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/288040
https://doi.org/10.1111/apt.17170
https://repository.ubn.ru.nl//bitstream/handle/2066/288040/288040.pdf
https://repository.ubn.ru.nl/handle/2066/288040
https://hdl.handle.net/20.500.11820/1e0b7bf4-02e1-4f5c-8e68-0063d70b292e
https://www.pure.ed.ac.uk/ws/files/301167268/Aliment_Pharmacol_Ther_2022_Chanchlani_Implications_for_sequencing_of_biologic_therapy_and_choice_of_second_anti_TNF.pdf -
20
Autoři: a další
Zdroj: Zhao, M, Lirhus, S, Lördal, M, Langholz, E, Knudsen, T, Voutilainen, M, Høivik, M L, Moum, B, Anisdahl, K, Sæbø, B, Haiko, P, Malmgren, C, Coskun, M, Melberg, H O & Burisch, J 2022, ' Therapeutic management and outcomes in inflammatory bowel diseases, 2010 to 2017 in cohorts from Denmark, Sweden and Norway ', Alimentary Pharmacology and Therapeutics, vol. 56, no. 6, pp. 989-1006 . https://doi.org/10.1111/apt.17145
Témata: Denmark, Crohn Disease/diagnosis, inflammatory bowel diseases, surgery, 03 medical and health sciences, 0302 clinical medicine, Crohn Disease, Inflammatory Bowel Diseases/drug therapy, Humans, Immunologic Factors, Sweden, Biological Products, hospitalisation, Norway, ta3121, Colitis, Inflammatory Bowel Diseases, Immunologic Factors/therapeutic use, Denmark/epidemiology, 3. Good health, Sweden/epidemiology, biological era, Ulcerative/diagnosis, epidemiology, Colitis, Ulcerative, Biological Products/therapeutic use
Popis souboru: application/pdf
Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/35902223
http://juuli.fi/Record/0399741422
http://juuli.fi/Record/0393554822
https://doi.org/10.1111/apt.17145
https://curis.ku.dk/ws/files/378959706/apt.17145_2_48.pdf
https://portal.findresearcher.sdu.dk/da/publications/cee95867-73e3-429c-88e4-19de4e551e31
https://doi.org/10.1111/apt.17145
Nájsť tento článok vo Web of Science 
Full Text Finder 
Full Text